[“In patients with type 2 diabetes, does probiotic ingestion decrease the incidence, quantity, and severity of GI adverse events associated with metformin treatment compared to metformin treatment alone?”,

“In adults with type 2 diabetes, how do lifestyle modifications such as caloric restriction and physical exercise compare to no specific lifestyle intervention or standard care without structured lifestyle modifications in improving HbA1c levels, achieving weight loss, and reducing triglyceride concentrations?”,

“In adults with type 2 diabetes who have not achieved adequate glycemic control with lifestyle changes, how does metformin compare to other antihyperglycemic drugs (such as sulfonylureas, insulin, or other antidiabetic medications) in reducing HbA1c levels, minimizing the risk of hypoglycemia and weight gain, and improving cardiovascular outcomes?”,

“In youth aged 10-17 years with type 2 diabetes, how does treatment with empagliflozin (10 mg or 25 mg) compared to placebo affect HbA1c levels after 26 weeks?”,

“In youth aged 10-17 years with type 2 diabetes, what is the incidence of adverse events when treated with empagliflozin (10 mg or 25 mg) or linagliptin (5 mg) compared to placebo up to 26 weeks?”,

“In youth aged 10-17 years with type 2 diabetes, how does treatment with empagliflozin (10 mg or 25 mg) compared to linagliptin (5 mg) affect HbA1c levels after 26 weeks?”,

“In adolescents aged 12-15 years, how effective is the BNT162b2 vaccine compared to a placebo in preventing COVID-19 infection?”,

“In individuals aged 16 years and older, what is the incidence and severity of adverse effects associated with the BNT162b2 vaccine compared to a placebo?”,

“In individuals aged 16 years and older, what is the efficacy of the first dose of the BNT162b2 vaccine compared to a placebo in preventing COVID-19 infection 12 days post-administration?”,

“In individuals vaccinated against diseases such as Herpes Zoster, Influenza, Rotavirus, and Pertussis, how effective is vaccination in reducing the severity of breakthrough disease compared to no vaccination as measured by the BOI score?”,

“In autologous hematopoietic stem cell transplantation (HSCT) recipients 18 years of age and older, how does the adjuvanted Recombinant Zoster Vaccine (RZV) compare to placebo in reducing the burden-of-illness (BOI) score for Herpes Zoster?”,

“In individuals participating in vaccine clinical trials, how does the adjusted vaccine efficacy (VE) based on burden-of-illness (BOI) scores compare to unadjusted VE when considering baseline covariates?”]